Results 131 to 140 of about 591 (191)
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors. [PDF]
Future OncolPowles T, Bhatia A, Burtness B, Kogawa T, Nishina T, Nakayama I, Fountzilas C, Castillo DR, McKean M, Meric-Bernstam F, Colombo N, Smithy JW, Fayette J, Chandra S, Sternberg DW, Jin F, Sullivan K, Yueh S, Clinthorne G, Aguilo AE, Kudchadkar R, Hayashi H. +21 moreeuropepmc +1 more sourceA First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. [PDF]
Clin Cancer ResKu G, Shen L, Dayyani F, Kratz J, Liang X, Liu F, Wang Z, Feller L, Girda E, Pan H, Kim S, Deng Y, Deng T, Liu T, Powderly J, Spencer K, Schneider R, Berlin J, Xu CC, Ahlers CM, Liu X, Chung JK, Sabbatini P, Park J, Lim Y, Jeon J, Meng Y, Klempner SJ. +27 moreeuropepmc +1 more sourceFirst-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors. [PDF]
J Immunother CancerRohrberg KS, Melero I, F Sanmamed M, Muñoz-Couselo E, Cervantes A, Gambardella V, Greillier L, Garrido P, Kim HR, Lee DH, Italiano A, Cassier PA, Hiret S, Deva S, Kim TM, Blumenschein GR, Løvendahl Eefsen R, Henick BS, Perro M, Umaña P, Peixoto A, Lauener L, Weber P, Seeber S, Klein C, Higgins B, Guidi M, Kraus D, Mücke M, Heichinger C, Tran VL, Schmid D, Michielin F, Liu T, McIntyre C, Kao H, Codarri Deak L, Markert C, Moreno V. +38 moreeuropepmc +1 more sourceA phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors. [PDF]
Front OncolGill D, Cowey CL, Daniels GA, Sommerhalder D, Abdul-Karim R, Kirkwood JM, Kolodney J, Mehmi I, Roberts-Thomson R, Strauss J, Thomas S, Whitman E, Xing Y, McKean M, Collins S, Li C, Saggu G, Chen T, Wang S, Lewis M, Parot X, Johnson M. +21 moreeuropepmc +1 more source605 Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)
Journal for ImmunoTherapy of CancerDrew Rasco, Meredith McKean, Ramaswamy Govindan, Nehal Lakhani, Sophia Frentzas, Andrew Weickhardt, Inbar Amit, Aron Knickerbocker, Yanay Ofran, Jenny Tang, Lori Richards, Catherine Oakman, George R Blumenschein, John D Powderly, Eric Lander, Jeffrey T Yorio, Timothy L Wyant, James R Vasselli +17 moredoaj +1 more sourcePhase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). [PDF]
J Immunother CancerDavar D, Cavalcante L, Lakhani N, Moser J, Millward M, McKean M, Voskoboynik M, Sanborn RE, Grewal JS, Narayan A, Patnaik A, Gainor JF, Sznol M, Enstrom A, Blanchfield L, LeBlanc H, Thomas H, Chisamore MJ, Peng SL, Naumovski A. +19 moreeuropepmc +1 more source611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study
Journal for ImmunoTherapy of CancerAndrew Haydon, Jose Lutzky, Siwen Hu-Lieskovan, Drew Rasco, Meredith McKean, Nehal Lakhani, Ganessan Kichenadasse, Vinod Ganju, Sophia Frentzas, Andrew Weickhardt, Aron Knickerbocker, Yanay Ofran, Jenny Tang, Lori Richards, Paul de Souza, John D Powderly, Eric Lander, Jeffrey T Yorio, Timothy L Wyant, James R Vasselli +19 moredoaj +1 more source